Brookline Capital Markets Comments on UNCY Q2 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Equities researchers at Brookline Capital Markets issued their Q2 2026 earnings per share estimates for Unicycive Therapeutics in a report released on Tuesday, April 7th. Brookline Capital Markets analyst K. Raja forecasts that the company will post earnings of ($0.34) per share for the quarter. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.36).

Several other brokerages also recently issued reports on UNCY. Guggenheim reduced their price objective on Unicycive Therapeutics from $46.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday, April 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a research report on Friday, March 27th. Westpark Capital began coverage on Unicycive Therapeutics in a research report on Thursday, February 19th. They issued a “buy” rating for the company. Finally, Benchmark cut their target price on Unicycive Therapeutics from $21.00 to $15.00 and set a “speculative buy” rating for the company in a research report on Monday. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.67.

Unicycive Therapeutics Trading Up 3.1%

Shares of NASDAQ UNCY opened at $6.65 on Thursday. The stock has a 50 day simple moving average of $6.64 and a 200-day simple moving average of $5.88. The company has a market cap of $167.83 million, a PE ratio of -3.06 and a beta of 1.81. Unicycive Therapeutics has a 12-month low of $3.71 and a 12-month high of $11.00.

Institutional Investors Weigh In On Unicycive Therapeutics

A number of institutional investors have recently added to or reduced their stakes in UNCY. Lazard Asset Management LLC acquired a new stake in Unicycive Therapeutics in the second quarter worth approximately $55,000. JPMorgan Chase & Co. lifted its position in Unicycive Therapeutics by 11,698.4% in the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after purchasing an additional 21,525 shares during the period. Citadel Advisors LLC acquired a new stake in Unicycive Therapeutics in the third quarter worth approximately $182,000. Quadrature Capital Ltd bought a new position in shares of Unicycive Therapeutics in the fourth quarter valued at $226,000. Finally, State Street Corp increased its holdings in shares of Unicycive Therapeutics by 19.0% in the fourth quarter. State Street Corp now owns 65,227 shares of the company’s stock valued at $376,000 after buying an additional 10,400 shares in the last quarter. 40.42% of the stock is currently owned by institutional investors and hedge funds.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.